A sponsor submitting a multi-country clinical trial application across Portugal and Spain needs the informed consent form in Portuguese and Spanish, each version approved by the relevant national ethics committee. A mistranslated sentence in the risks section can send the whole document back for correction, delaying approval by weeks. Regulation (EU) 536/2014 harmonised much of the clinical trial application process across member states, but it did not remove the core requirement: the participant must understand, in their own language, exactly what they are agreeing to.
What Regulation 536/2014 requires for participant information
Article 29 of Regulation 536/2014 states that information given to a trial subject must be complete, concise, clear, relevant, and understandable to a layperson. This is not a drafting preference. It is a condition for the validity of the consent itself.
The informed consent form (ICF) typically covers:
- The nature, objectives, duration and procedures of the trial
- Foreseeable risks and expected benefits
- Available treatment alternatives
- The participant's right to withdraw, without consequence for their care
- Data protection, under GDPR and applicable national data protection law
- Contact details for the investigator and the ethics committee
Each of these sections carries different legal weight depending on the country. The data protection section, for instance, needs to reflect both GDPR and the national data protection framework of the country where the trial is running.
Why this document needs a higher level of review than most
The ICF is not written for specialists. It is written for a patient, often in a vulnerable position, who may have no medical background. That creates a genuine tension in translation: the source text uses precise clinical terminology, and the translated version has to keep that precision while remaining understandable to a non-expert reader.
A literal rendering of terms such as "placebo-controlled", "adverse event" or "randomisation" can be technically accurate and still leave the participant unclear about what they are signing. The skill is adjusting the register without changing the clinical meaning. In multi-site trials, that adjustment also has to stay consistent with the trial protocol and other related documents, a point we cover in detail in our article on translating clinical trial protocols for regulatory submission.
For this reason, informed consent forms, like contracts and regulatory submissions, should always run through the Estratégica service tier: three linguists (translator, reviewer and QA reviewer), an ISO 17100 audited workflow, two post-delivery revision rounds and a dedicated project manager. It is the only tier that includes review by a second linguist (translation, editing and proofreading), and it is the appropriate standard for a document where a meaning error has a direct effect on the validity of a participant's consent.
Ethics committees, national languages and submission timing
Each member state still sets its own language requirement for the national ethics committee review, even with Regulation 536/2014 standardising the procedure through the Clinical Trials Information System (CTIS). Participant-facing documents in Portugal must be in Portuguese. In multi-country trials involving Spain, France or Germany, each country requires its own language version, and the ethics committee reviews run in parallel, not one after another.
This has a direct planning consequence. If the ICF is only translated once the protocol is finalised in English, the sponsor loses time that could have been gained by translating alongside protocol development. ICF translation should start as soon as the master protocol version is stable, not after approval lands in another country. Consent forms are often paired with other trial documentation, such as investigational product labelling, which follows a similar translation logic, as covered in our article on drug labelling translation.
Several factors affect the real delivery timeline: the number of languages involved, the clinical complexity of the protocol, whether terminology needs harmonising across multiple trial sites, and whether the document requires certification for formal submission. None of these has a fixed value, which is why each ICF translation project needs its own quote.
How M21Global handles informed consent form translation
M21Global is certified to ISO 17100:2015 (Bureau Veritas) and ISO 18587 for machine translation post-editing, and has translated over 445 million words across more than 20 years in the field. For informed consent forms, we apply the Estratégica tier by default, with validated terminology in each target language and consistency maintained across the ICF, the protocol, and the rest of the trial's regulatory dossier, handled under our pharmaceutical translation service.
If the trial involves a combination product alongside the investigational drug, it is worth reviewing the specific requirements under the MDR, detailed in our article on medical device documentation translation under MDR. Request a quote from M21Global and receive a response within three business hours, with a clear outline of the translation and review process that applies to your ICF.
Related Services
Request a free medical translation quote
- Request a free medical translation quote
- Medical Device Documentation Translation Mdr Compliance
- Translating Clinical Trial Protocols Regulatory Submission
- Drug Labeling Translation
Frequently Asked Questions
What does Regulation 536/2014 say about informed consent translation?
Article 29 requires that information given to trial participants be complete, concise, clear and understandable to a layperson, which applies to every language version used across member states.
What language does an informed consent form need to be in for a trial in Portugal?
It must be in Portuguese, regardless of the original language of the trial protocol.
Which service level is appropriate for translating an ICF?
The Estratégica tier, which includes a translator, reviewer and QA reviewer under an ISO 17100 audited workflow with two post-delivery revision rounds, because it is the only tier with review by a second linguist.
When should ICF translation start in a multi-country trial?
As soon as the master protocol version is stable, so translation can run in parallel with ethics committee submissions in each country rather than starting after approval elsewhere.
Does informed consent form translation need certification?
It depends on the specific ethics committee or authority receiving it; what matters most is a traceable translation and review process, which an ISO 17100 audited workflow provides.
